{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '68', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Table 2', 'Study Interventions', 'Arm', 'Intervention', 'Dose', 'Unit Dose', 'Regimen/', 'Dosage', 'Route of', 'IMP/', 'Arm Type', 'Type', 'Treatment', 'Use', 'Name', 'Name', 'Formulation', 'Strength(s)', 'Administration', 'Sourcing', 'Level(s)', 'NIMP', 'Period', 'Arm A', 'Experimental', 'Pembrolizumab', 'Drug', 'Solution for', '25 mg/mL', '200 mg', 'IV Infusion', 'Q3W', 'Standard of', 'IMP', 'Provided', 'and B', '(MK-3475)', 'Infusion', 'care/', 'centrally', 'Experimental', 'by the', 'Sponsor', 'ArmA', 'Experimental', 'Lenvatinib', 'Drug', 'Capsule', '10 mg/4 mg', '20 mg', 'Oral', 'QD', 'Experimental', 'IMP', 'Provided', '(E7080/', 'centrally', 'MK -7902)', 'by the', 'Sponsor', 'Arm B', 'Placebo', 'Placebo', 'Drug', 'Capsule', 'NA', 'NA', 'Oral', 'QD', 'Placebo', 'IMP', 'Provided', 'Comparator', 'centrally', 'by the', 'Sponsor', 'Abbreviations: EEA = European Economic Area; IMP = investigational medicinal product; IV = intravenous; NA = not applicable; NIMP = noninvestigational medicinal product;', 'Q3W = every 3 weeks; QD = once daily.', 'The classification of IMP in this table is based on guidance issued by the European Commission and applies to countries in the EEA. Country differences with respect to the', 'definition/classification of IMP/NIMP may exist. In these circumstances, local legislation is followed.', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed from the treatment groups. Participants remaining on treatment will receive', 'open-label pembrolizumab monotherapy as per protocol. The original study interventions and updates are indicated by strikethrough in the table.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '69', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'All supplies indicated in Table 2 will be provided per the \"Sourcing\" column depending upon', 'local country operational requirements. If local sourcing, every attempt should be made to', 'source these supplies from a single lot/batch number.', 'Refer to Section 8.1.8 for details regarding administration of the study intervention.', 'All placebos were created by the Sponsor to match the active product.', '6.1.1', 'Medical Devices', 'This section is not applicable.', '6.2', 'rreparation/Handling/Storage/Accountability', '6.2.1', 'Dose Preparation', 'Details on the preparation and administration of pembrolizumab are provided in the', 'Pharmacy Manual. Lenvatinib is a capsule for oral administration and does not require', \"preparation. Before protocol amendment 007-06, site's staff referred to the Pharmacy Manual\", 'for lenvatinib administration.', 'The rationale for selection of doses to be used in this study is provided in Section 4.3.', '6.2.2', 'Handling, Storage, and Accountability', 'Details on preparation and administration of IV pembrolizumab are provided in the', 'Pharmacy Manual. Participants/caregivers were given instructions on how to handle and', 'store lenvatinib/matching placebo capsules at home until it was discontinued as per Protocol', 'Amendment 007-06.', 'The investigator or designee must confirm appropriate temperature conditions have been', 'maintained during transit for all study intervention received, and any discrepancies are', 'reported and resolved before use of the study intervention.', 'Only participants enrolled in the study may receive study intervention, and only authorized', 'site staff may supply or administer study intervention. All study interventions must be stored', 'in a secure, environmentally controlled, and monitored (manual or automated) area in', 'accordance with the labeled storage conditions with access limited to the investigator and', 'authorized site staff.', 'The investigator, institution, or the head of the medical institution (where applicable) is', 'responsible for study intervention accountability, reconciliation, and record maintenance (ie,', 'receipt, reconciliation, and final disposition records).', 'For all study sites, the local country Sponsor personnel or designee will provide appropriate', 'documentation that must be completed for drug accountability and return, or local discard', 'and destruction if appropriate. Where local discard and destruction is appropriate, the', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}